Introduction
Double hit B-cell lymphomas with concurrent MYC and BCL2 rearrangements are well described and are associated with a rapidly progressive clinical course and dismal prognosis. Cases of double hit myeloma however, are rare, and there are no reported cases of double hit plasma cell leukemia. Here, we describe the case of an aggressive plasma cell leukaemia characterised by simultaneous IGH/MYC and IGH/BCL2 translocations. Two new cell lines have subsequently been derived from this case.
The case
A 42-year-old female was referred to hospital with a one-week history of blurred vision and bone pain on a background of three months of weight loss and lethargy. Physical examination was remarkable for a proptosed left eye and moderate hepatosplenomegaly. Overall, the findings were consistent with a diagnosis of primary plasma cell leukemia (pPCL).
The patient was administered intravenous dexamethasone 40mg and supportive therapy, which consisted of hydration and rasburicase and allopurinol. However, Cell surface expression of CXCR4 and CD45 were analysed by flow cytometry using commercially available conjugated antibodies from BD Biosciences. ALF-1 and ALF-2 were cultured from the peripheral blood and bone marrow aspirate respectively. ALF-1 had lower levels of CXCR4 expression (A), consistent with its key roles in metastasis, tumour cell extravasation and dissemination from the primary tumour site; and lower levels of CD45 expression (B) compared to ALF-2 which is associated with disease progression and adverse clinical outcome.
